|[June 27, 2014]
Dr. Reddy's Laboratories Limited Announces Filing of Annual Report on Form 20-F
HYDERABAD, India --(Business Wire)--
Dr. Reddy's Laboratories Limited (NYSE: RDY) today announced that its
Annual Report on Form 20-F, containing its annual consolidated financial
statements for the fiscal year ended 31 March, 2014 was filed with the
United States Securities and Exchange Commission on June 26, 2014.
The Annual Report on Form 20-F is also available on Dr. Reddy's website, www.drreddys.com,
and can be accessed by selecting 'SEC (News - Alert) filings' under the 'Investors'
Section. ADS holders may also obtain a hard copy of the Annual Report on
Form 20-F at no cost, by sending a written request to the Company's
registered office or by sending an e-mail to firstname.lastname@example.org.
This press release includes forward-looking statements, as defined in
the U.S. Private Securities Litigation Reform Act of 1995. We have based
these forward-looking statements on our current expectations and
projections about future events. Such statements involve known and
unknown risks, uncertainties and other factors that may cause actual
results to differ materially. Such factors include, but are not limited
to, changes in local and global economic conditions, our ability to
successfully implement our strategy, the market acceptance of and demand
for our products, our growth and expansion, technological change and our
exposure to market risks. By their nature, these expectations and
projections are only estimates and could be materially different from
actual results in the future.
About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is an integrated global
pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses -
Pharmaceutical Services and Active Ingredients, Global Generics and
Proprietary Products - Dr. Reddy's offers a portfolio of products and
services including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Major therapeutic focus is
on gastro-intestinal, cardiovascular, diabetology, oncology, pain
management and anti-infective. Major markets include India, USA,
Russia-CIS and Europe apart from other select geographies within
Emerging Markets. For more information, log on to: www.drreddys.com.
[ Back To TMCnet.com's Homepage ]